OPTIMIERTE FAKTOR-VIII-GENE

European patent · EP3411478 · In force

Register entry

Publication number
EP3411478
Application number
EP17705236
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jan 31, 2017
Published
Dec 12, 2018
Granted
Jun 8, 2022
Protection ends at the latest
Jan 30, 2037
Next annual fee due
Jan 31, 2027
IPC classes
C12N 9/64 (2006.01)
Priority
US 201662289696 P 01.02.2016
US 201662409739 P 18.10.2016
PCT application
PCT/US2017/015879 31.01.2017
PCT publication
WO2017/136358 10.08.2017
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 1, 2026

    Change

    Published in Swissreg on 01.02.2026

  2. Feb 1, 2025

    Change

    Published in Swissreg on 01.02.2025

  3. Feb 1, 2024

    Change

    Published in Swissreg on 01.02.2024

  4. Apr 19, 2023

    Change

    Published in Swissreg on 19.04.2023

  5. Feb 1, 2023

    Change

    Published in Swissreg on 01.02.2023

  6. Jun 8, 2022

    Granted

    Published in Swissreg on 08.06.2022

Parties

Holder

Bioverativ Therapeutics Inc.

225 Second Avenue, Waltham, MA 02451, US

Inventor

LIU, Tongyao

Lexington, Massachusetts 02421, US

TAN, Siyuan

Lexington, Massachusetts 02421, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.